NEW YORK, Nov. 11 (GenomeWeb News) - Third Wave Technologies expects revenues from clinical molecular diagnostic products to expand to between $23 million and $26 million in 2005, the company said today.

The company said the revenue will be "driven chiefly by the company's core genetics, cystic fibrosis and HCV genotyping reagents."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.